There is a new development! The recombinant new crown protein vaccine developed by Sichuan University West China Hospital is scheduled to be vaccinated in Chengdu from the 13th

Read Time:1 Minute, 59 Second

On January 11, the reporter learned that the recombinant new coronavirus protein vaccine (Sf9 cells) developed by the West China Hospital of Sichuan University, Vicksin, has been approved for entry and is scheduled to be the first to be vaccinated in Chengdu on January 13.

On December 14, 2022, the joint prevention and control mechanism of the State Council issued a notice on the issuance of the second dose of new coronavirus vaccine booster immunization implementation plan, and the combination of vaccine selection plan includes “3 doses of inactivated vaccine + 1 dose of Chengdu Weiskin recombinant new coronavirus vaccine (sf9 cells)”.

On December 5, 2022, the recombinant new coronavirus protein vaccine (Sf9 cells) developed by West China Hospital of Sichuan University was approved for emergency use by the relevant national authorities. This is the first recombinant protein novel coronavirus protein vaccine produced by the insect cell technology platform approved for emergency use in China, and the first new coronavirus vaccine approved for emergency use led by a hospital in China.

The first recombinant new coronavirus protein vaccine developed by West China Hospital of Sichuan University was approved for emergency use

In early 2020, after the outbreak of New Coronavirus pneumonia, a team of scientists from the State Key Laboratory of Biological Therapy at West China Hospital of Sichuan University received a project and funding from the State Council’s Joint Prevention and Control Mechanism Scientific Research and Development Group Vaccine R&D Special Class, which is one of the five state-funded technical routes for New Coronavirus vaccine R&D.

It is understood that the data show that Vaxin can significantly induce neutralizing antibodies against the prototype and variant strains of NCCV, and that sequential booster immunization can obtain stronger immune response based on the existing vaccine immunization. In terms of preparation technology, Wicresin uses internationally advanced production technology to introduce the genes of the neo-coronavirus into insect cells to produce the neo-coronavirus S protein, which induces antibodies in humans to block virus infection and has been produced on a large scale. The use of insect cells to produce recombinant neo-coronavirus vaccine not only has good protein expression quality, but also has high safety. This technical route has been applied to vaccine production internationally, and products such as recombinant protein vaccines for influenza vaccine and cervical cancer vaccine have been marketed.